Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KPI-012
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KPI-012 is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially treat persistent corneal epithelial defect (PCED).
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 12, 2023
Lead Product(s) : KPI-012
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KPI-012
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KPI-012 is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially treat persistent corneal epithelial defect (PCED).
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 27, 2023
Lead Product(s) : KPI-012
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KPI-012
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Kala Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED
Details : KPI-012 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Corneal Diseases.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 14, 2023
Lead Product(s) : KPI-012
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Kala Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KPI-012
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, it has the potential to correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 27, 2022
Lead Product(s) : KPI-012
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KPI-012
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KPI-012, is human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors can potentially correct impaired corneal healing that is an underlying etiology of multiple s...
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 28, 2022
Lead Product(s) : KPI-012
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KPI-012
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : $31.0 million
Deal Type : Private Placement
Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing
Details : Kala intends to use proceeds from the financing to advance the clinical development of KPI-012 for the treatment of PCED, as well as for general corporate purposes.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
November 28, 2022
Lead Product(s) : KPI-012
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : $31.0 million
Deal Type : Private Placement
Lead Product(s) : Loteprednol Etabonate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Alcon Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Alcon to Acquire EYSUVIS Adding to Its Ophthalmic Eye Drop Portfolio
Details : The acquisition will complement Alcon’s existing portfolio in the large and fast-growing dry eye category. EYSUVIS (Loteprednol Etabonate) will complement the Systane® family of eye drops which includes the recently launched Systane Preservative-Free ...
Product Name : Eysuvis
Product Type : Steroid
Upfront Cash : $60.0 million
May 23, 2022
Lead Product(s) : Loteprednol Etabonate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Alcon Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : KPI-012
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data for CMB-012 (KPI-012), demonstrated rapid and complete wound healing, with six of eight (75%) patients achieving complete healing within four weeks; all remained healed through end of follow-up.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 01, 2022
Lead Product(s) : KPI-012
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KPI-012
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KPI-012, a novel investigational secretome therapy, initially targeting persistent corneal epithelial defects and multiple proprietary new chemical entity preclinical development programs targeted to address unmet medical needs, including both front and ...
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 04, 2022
Lead Product(s) : KPI-012
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Loteprednol Etabonate
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Recipient : Price Vision Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
Details : Loteprednol Etabonate is a Steroid drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Corneal Endothelial Dystrophy.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
November 29, 2021
Lead Product(s) : Loteprednol Etabonate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Recipient : Price Vision Group
Deal Size : Inapplicable
Deal Type : Inapplicable